miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Li, Jipeng ^a   Wang, Yiping ^a   Song, Yulan ^a   Fu, Zhongming ^a   Yu, Wanjun ^a  

^a Yinzhou People's Hospital   (China)

Author keywords

Chemoresistance; Cisplatin; Lung adenocarcinoma; miR 27a; RKIP

Indexed keywords

CISPLATIN; MICRORNA; MIR 27A; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MIRN27 MICRORNA, HUMAN; PEBP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICRORNAS; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

EID: 84934901525     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-193     Document Type: Article

References (35)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Gupta GP, Massague J: Cancer metastasis: building a framework. Cell 2006, 127:679-695.
4. Goldman B: Multidrug resistance: can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 2003, 95:255-257.
5. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V: Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 2012, 72:4883-4889.
6. Sato M, Shames DS, Gazdar AF, Minna JD: A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007, 2:327-343.
7. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F: Chemoresistance to paclitaxel induces epithelialmesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007, 31:277-283.
8. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI: Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006, 118:290-301.
9. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray M, Cheng H, Hoff PM, Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006, 12:4147-4153.
10. Sun L, Yao Y, Liu B, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, Song E, Li J: miR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tonge cancer cells by targeting BMI1. Oncogene 2012, 31:432-445.
11. Singh A, Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
12. Gordeladze JO, Djouad F, Brondello JM, Duroux-Richard I, Apparailly F, Jorgensen C: Concerted stimuli regulating osteo-chondral differentiation from stem cells: phenotype acquisition regulated by microRNAs. Acta Pharmacol Sin 2009, 30:1369-1384.
13. Wu F, Yang Z, Li G: Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun 2009, 386:549-553.
14. Skaftnesmo KO, Prestegarden L, Micklem DR, Lorens JB: MicroRNAs in tumorigenesis. Curr Pharm Biotechnol 2007, 8:320-325.
15. Van Jaarsveld MT, Helleman J, Boersma AW, Van Kuijk PF, Van Ljchen WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA: miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013, 32:4284-4293.
16. Zhang Y, Lu Q, Cai X: MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013, 587:3069-3075.
17. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S: The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007, 67:11001-11011.
18. Huang D, Wang H, Liu R, Li H, Ge S, Bai M, Deng T, Yao G, Ba Y: miR-27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem 2014, 15:549-556.
19. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008, 3:e2557.
20. Zhao X, Yang L, Hu J: Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011, 30:55.
21. Zhang Z, Liu S, Shi R, Zhao G: miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. Cancer Genet 2011, 204:486-491.
22. Tang W, Yu F, Yao H, Cui X, Jiao Y, Lin L, Chen J, Yin D, Song E, Liu Q: miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 2014, 33:2629-2638.
23. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z: MiR-27a modulates MDR1/Pglycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 2010, 119:125-130.
24. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, Zheng X: Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010, 55:2545-2551.
25. Granovsky AE, Rosner MR: Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res 2008, 18:452-457.
26. Escara-Wilke J, Yeung K, Keller ET: Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev 2012, 31:615-620.
27. Das SK, Bhutia SK, Sokhi UK, Azab B, Su ZZ, Boukerche H, Anwar T, moen EL, Chatterjee D, Pellecchia M, Sarkar D, Fiser PB: Raf kinase inhibitor RKIP inhibits MDA-9/syntenin-mediated metastasis in melanoma. Cancer Res 2012, 72:6217-6226.
28. Zhang XM, Gu H, Yan L, Zhang GY: RKIP inhibits the malignant phenotypes of gastric cancer cells. Neoplasma 2013, 60:196-202.
29. Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A: Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br J Cancer 2013, 108:2088-2096.
30. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC: Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2008, 27:2243-2248.
31. Martinho O, Pinto F, Granja S, Miranda-Goncalves V, Moreira MA, Ribeiro LF, di Loreto C, Rosner MR, Longatto-Filho A, Reis RM: RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy. PLoS One 2013,8(3):e59104.
32. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G: Identification of microRNA-21as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010, 5:e10630.
33. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, Mori M: MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 2012, 19:3065-3071.
34. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H: Circulating miR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012, 7:e34210.
35. Tsang WP, Kwok TT: The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009, 30:953-959.